tiprankstipranks
Jazz Pharmaceuticals (JAZZ)
NASDAQ:JAZZ
US Market
JAZZ
Jazz Pharmaceuticals
RESEARCH TOOLSreports
Want to see JAZZ full AI Analyst Report?

Jazz Pharmaceuticals (JAZZ) Stock Forecast & Price Target

1,901 Followers
See the Price Targets and Ratings of:

JAZZ Analyst Ratings

Strong Buy
18Ratings
Strong Buy
17 Buy
1 Hold
0 Sell
Based on 18 analysts giving stock ratings to
Jazz
Pharmaceuticals
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

JAZZ Stock 12 Month Forecast

Average Price Target

$281.33
▲(10.82% Upside)
Based on 18 Wall Street analysts offering 12 month price targets for Jazz Pharmaceuticals in the last 3 months. The average price target is $281.33 with a high forecast of $315.00 and a low forecast of $229.00. The average price target represents a 10.82% change from the last price of $253.87.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"114":"$114","215":"$215","316":"$316","164.5":"$164.5","265.5":"$265.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":315,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$315.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":281.3333333333333,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$281.33</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":229,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$229.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[114,164.5,215,265.5,316],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,252.86,257.64,262.42,267.2,271.98,276.76,281.54,286.32,291.1,295.88,300.66,305.44,310.22,{"y":315,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,252.86,255.05025641025642,257.24051282051283,259.4307692307692,261.62102564102565,263.81128205128203,266.0015384615385,268.19179487179485,270.3820512820513,272.5723076923077,274.7625641025641,276.9528205128205,279.14307692307693,{"y":281.3333333333333,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,252.86,251.0246153846154,249.1892307692308,247.35384615384618,245.51846153846154,243.68307692307692,241.8476923076923,240.0123076923077,238.1769230769231,236.34153846153848,234.50615384615384,232.67076923076922,230.8353846153846,{"y":229,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":115.52,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":129.66,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":136.9,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":137.64,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":172.12,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":170,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":167.29,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":190.46,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":188.27,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":202.72,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":232.64,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":237.51,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":252.86,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$315.00Average Price Target$281.33Lowest Price Target$229.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Canaccord Genuity Analyst forecast on JAZZ
Gary Nachman
Canaccord Genuity
Canaccord Genuity
$290→$300
Buy
18.17%
Upside
Reiterated
08/05/26
Jazz Pharmaceuticals price target raised to $300 from $290 at CanaccordJazz Pharmaceuticals price target raised to $300 from $290 at Canaccord
Needham Analyst forecast on JAZZ
Ami Fadia
Needham
Needham
$292
Buy
15.02%
Upside
Assigned
08/04/26
Jazz Pharmaceuticals: Buy Rating Reaffirmed as Strong Q2 Results, Growth Franchises, and Pipeline Upside Drive Price-Target Increase
Barclays Analyst forecast on JAZZ
Etzer Darout
Barclays
Barclays
$260→$270
Buy
6.35%
Upside
Reiterated
08/04/26
Analysts Offer Insights on Healthcare Companies: Jazz Pharmaceuticals (NASDAQ: JAZZ) and Inspire Medical Systems (NYSE: INSP)
TD Cowen Analyst forecast on JAZZ
Joseph Thome
TD Cowen
TD Cowen
$275→$300
Buy
18.17%
Upside
Assigned
08/04/26
Analysts Offer Insights on Healthcare Companies: HealthStream (NASDAQ: HSTM) and Jazz Pharmaceuticals (NASDAQ: JAZZ)
Piper Sandler Analyst forecast on JAZZ
David Amsellem
Piper Sandler
Piper Sandler
$301→$310
Buy
22.11%
Upside
Reiterated
08/04/26
Piper Sandler Keeps Their Buy Rating on Jazz Pharmaceuticals (JAZZ)
Truist Financial Analyst forecast on JAZZ
Gregory Renza
Truist Financial
Truist Financial
$254→$264
Buy
3.99%
Upside
Reiterated
08/04/26
Truist Financial Reaffirms Their Buy Rating on Jazz Pharmaceuticals (JAZZ)
Stifel Nicolaus Analyst forecast on JAZZ
Annabel Samimy
Stifel Nicolaus
Stifel Nicolaus
$230→$275
Buy
8.32%
Upside
Reiterated
08/04/26
Stifel Nicolaus Remains a Buy on Jazz Pharmaceuticals (JAZZ)
Morgan Stanley Analyst forecast on JAZZ
Sean Laaman
Morgan Stanley
Morgan Stanley
$245→$280
Buy
10.29%
Upside
Assigned
08/04/26
Jazz Pharmaceuticals: Buy Rating Reaffirmed as Strong Momentum and Emerging Oncology Catalysts Drive Price Target Increase to $280
Deutsche Bank Analyst forecast on JAZZ
David Hoang
Deutsche Bank
Deutsche Bank
$270→$287
Buy
13.05%
Upside
Assigned
08/04/26
Jazz Pharmaceuticals price target raised to $287 from $270 at Deutsche BankJazz Pharmaceuticals price target raised to $287 from $270 at Deutsche Bank
J.P. Morgan Analyst forecast on JAZZ
Jessica Fye
J.P. Morgan
J.P. Morgan
$265→$276
Buy
8.72%
Upside
Assigned
08/04/26
Jazz Pharmaceuticals (JAZZ) Receives a Buy from J.P. Morgan
UBS Analyst forecast on JAZZ
Ashwani Verma
UBS
UBS
$307→$315
Buy
24.08%
Upside
Reiterated
08/04/26
Jazz Pharmaceuticals (JAZZ) Receives a Buy from UBS
Robert W. Baird Analyst forecast on JAZZ
Brian Skorney
Robert W. Baird
Robert W. Baird
$252→$280
Buy
10.29%
Upside
Reiterated
08/04/26
Jazz Pharmaceuticals price target raised to $280 from $252 at BairdJazz Pharmaceuticals price target raised to $280 from $252 at Baird
Bank of America Securities Analyst forecast on JAZZ
Jason Gerberry
Bank of America Securities
Bank of America Securities
$307
Buy
20.93%
Upside
Reiterated
08/03/26
Jazz Pharmaceuticals: Buy Rating Reiterated on Strong Q2 Performance and Oxybate Franchise Momentum; $307 Price Target Maintained
Wells Fargo Analyst forecast on JAZZ
Mohit Bansal
Wells Fargo
Wells Fargo
$285→$300
Buy
18.17%
Upside
Assigned
08/03/26
Jazz Pharmaceuticals (JAZZ) Receives a Buy from Wells Fargo
RBC Capital Analyst forecast on JAZZ
Leonid Timashev
RBC Capital
RBC Capital
$258
Buy
1.63%
Upside
Reiterated
07/31/26
RBC Capital Sticks to Their Buy Rating for Jazz Pharmaceuticals (JAZZ)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Canaccord Genuity Analyst forecast on JAZZ
Gary Nachman
Canaccord Genuity
Canaccord Genuity
$290→$300
Buy
18.17%
Upside
Reiterated
08/05/26
Jazz Pharmaceuticals price target raised to $300 from $290 at CanaccordJazz Pharmaceuticals price target raised to $300 from $290 at Canaccord
Needham Analyst forecast on JAZZ
Ami Fadia
Needham
Needham
$292
Buy
15.02%
Upside
Assigned
08/04/26
Jazz Pharmaceuticals: Buy Rating Reaffirmed as Strong Q2 Results, Growth Franchises, and Pipeline Upside Drive Price-Target Increase
Barclays Analyst forecast on JAZZ
Etzer Darout
Barclays
Barclays
$260→$270
Buy
6.35%
Upside
Reiterated
08/04/26
Analysts Offer Insights on Healthcare Companies: Jazz Pharmaceuticals (NASDAQ: JAZZ) and Inspire Medical Systems (NYSE: INSP)
TD Cowen Analyst forecast on JAZZ
Joseph Thome
TD Cowen
TD Cowen
$275→$300
Buy
18.17%
Upside
Assigned
08/04/26
Analysts Offer Insights on Healthcare Companies: HealthStream (NASDAQ: HSTM) and Jazz Pharmaceuticals (NASDAQ: JAZZ)
Piper Sandler Analyst forecast on JAZZ
David Amsellem
Piper Sandler
Piper Sandler
$301→$310
Buy
22.11%
Upside
Reiterated
08/04/26
Piper Sandler Keeps Their Buy Rating on Jazz Pharmaceuticals (JAZZ)
Truist Financial Analyst forecast on JAZZ
Gregory Renza
Truist Financial
Truist Financial
$254→$264
Buy
3.99%
Upside
Reiterated
08/04/26
Truist Financial Reaffirms Their Buy Rating on Jazz Pharmaceuticals (JAZZ)
Stifel Nicolaus Analyst forecast on JAZZ
Annabel Samimy
Stifel Nicolaus
Stifel Nicolaus
$230→$275
Buy
8.32%
Upside
Reiterated
08/04/26
Stifel Nicolaus Remains a Buy on Jazz Pharmaceuticals (JAZZ)
Morgan Stanley Analyst forecast on JAZZ
Sean Laaman
Morgan Stanley
Morgan Stanley
$245→$280
Buy
10.29%
Upside
Assigned
08/04/26
Jazz Pharmaceuticals: Buy Rating Reaffirmed as Strong Momentum and Emerging Oncology Catalysts Drive Price Target Increase to $280
Deutsche Bank Analyst forecast on JAZZ
David Hoang
Deutsche Bank
Deutsche Bank
$270→$287
Buy
13.05%
Upside
Assigned
08/04/26
Jazz Pharmaceuticals price target raised to $287 from $270 at Deutsche BankJazz Pharmaceuticals price target raised to $287 from $270 at Deutsche Bank
J.P. Morgan Analyst forecast on JAZZ
Jessica Fye
J.P. Morgan
J.P. Morgan
$265→$276
Buy
8.72%
Upside
Assigned
08/04/26
Jazz Pharmaceuticals (JAZZ) Receives a Buy from J.P. Morgan
UBS Analyst forecast on JAZZ
Ashwani Verma
UBS
UBS
$307→$315
Buy
24.08%
Upside
Reiterated
08/04/26
Jazz Pharmaceuticals (JAZZ) Receives a Buy from UBS
Robert W. Baird Analyst forecast on JAZZ
Brian Skorney
Robert W. Baird
Robert W. Baird
$252→$280
Buy
10.29%
Upside
Reiterated
08/04/26
Jazz Pharmaceuticals price target raised to $280 from $252 at BairdJazz Pharmaceuticals price target raised to $280 from $252 at Baird
Bank of America Securities Analyst forecast on JAZZ
Jason Gerberry
Bank of America Securities
Bank of America Securities
$307
Buy
20.93%
Upside
Reiterated
08/03/26
Jazz Pharmaceuticals: Buy Rating Reiterated on Strong Q2 Performance and Oxybate Franchise Momentum; $307 Price Target Maintained
Wells Fargo Analyst forecast on JAZZ
Mohit Bansal
Wells Fargo
Wells Fargo
$285→$300
Buy
18.17%
Upside
Assigned
08/03/26
Jazz Pharmaceuticals (JAZZ) Receives a Buy from Wells Fargo
RBC Capital Analyst forecast on JAZZ
Leonid Timashev
RBC Capital
RBC Capital
$258
Buy
1.63%
Upside
Reiterated
07/31/26
RBC Capital Sticks to Their Buy Rating for Jazz Pharmaceuticals (JAZZ)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
AVBPArriVent BioPharma, Inc.
BTSGBrightSpring Health Services, Inc.
MLYSMineralys Therapeutics, Inc.
ZURAZura Bio
TNYATenaya Therapeutics
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Jazz Pharmaceuticals

3 Months
Jason GerberryBank of America Securities
Success Rate
20/29 ratings generated profit
69%
Average Return
+4.21%
Copying Jason Gerberry's trades and holding each position for 3 Months would result in 68.97% of your transactions generating a profit, with an average return of +4.21% per trade.
1 Year
Joseph ThomeTD Cowen
Success Rate
19/21 ratings generated profit
90%
Average Return
+43.27%
Copying Joseph Thome's trades and holding each position for 1 Year would result in 90.48% of your transactions generating a profit, with an average return of +43.27% per trade.
2 Years
Joseph ThomeTD Cowen
Success Rate
20/21 ratings generated profit
95%
Average Return
+80.99%
Copying Joseph Thome's trades and holding each position for 2 Years would result in 95.24% of your transactions generating a profit, with an average return of +80.99% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

JAZZ Analyst Recommendation Trends

Rating
Apr 26
May 26
Jun 26
Jul 26
Aug 26
Strong Buy
0
0
0
0
0
Buy
22
25
31
35
34
Hold
0
2
4
4
2
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
22
27
35
39
36
In the current month, JAZZ has received 34 Buy Ratings, 2 Hold Ratings, and 0 Sell Ratings. JAZZ average Analyst price target in the past 3 months is 281.33.
Each month's total comprises the sum of three months' worth of ratings.

JAZZ Financial Forecast

JAZZ Earnings Forecast

Next quarter’s earnings estimate for JAZZ is $6.48 with a range of $5.81 to $7.11. The previous quarter’s EPS was $5.71. JAZZ beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.82% of the time in the same period. In the last calendar year JAZZ has Performed in-line its overall industry.
Next quarter’s earnings estimate for JAZZ is $6.48 with a range of $5.81 to $7.11. The previous quarter’s EPS was $5.71. JAZZ beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.82% of the time in the same period. In the last calendar year JAZZ has Performed in-line its overall industry.

JAZZ Sales Forecast

Next quarter’s sales forecast for JAZZ is $1.21B with a range of $1.18B to $1.24B. The previous quarter’s sales results were $1.21B. JAZZ beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.46% of the time in the same period. In the last calendar year JAZZ has Performed in-line its overall industry.
Next quarter’s sales forecast for JAZZ is $1.21B with a range of $1.18B to $1.24B. The previous quarter’s sales results were $1.21B. JAZZ beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.46% of the time in the same period. In the last calendar year JAZZ has Performed in-line its overall industry.

JAZZ Stock Forecast FAQ

What is JAZZ’s average 12-month price target, according to analysts?
Based on analyst ratings, Jazz Pharmaceuticals’s 12-month average price target is 281.33.
    What is JAZZ’s upside potential, based on the analysts’ average price target?
    Jazz Pharmaceuticals has 10.82% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is JAZZ a Buy, Sell or Hold?
          Jazz Pharmaceuticals has a consensus rating of Strong Buy which is based on 17 buy ratings, 1 hold ratings and 0 sell ratings.
            What is Jazz Pharmaceuticals’s price target?
            The average price target for Jazz Pharmaceuticals is 281.33. This is based on 18 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $315.00 ,the lowest forecast is $229.00. The average price target represents 10.82% Increase from the current price of $253.87.
              What do analysts say about Jazz Pharmaceuticals?
              Jazz Pharmaceuticals’s analyst rating consensus is a Strong Buy. This is based on the ratings of 18 Wall Streets Analysts.
                How can I buy shares of JAZZ?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.